Shares of Humana Inc (NYSE:HUM) climbed on Tuesday following the U.S. government's release of final Medicare Advantage (MA) rate guidance for 2027. The Centers for Medicare & Medicaid Services (CMS) set an expected rate increase of 2.48% for 2027, a sizeable revision from the nearly flat 0.09% increase that had been outlined in the preliminary Advance Notice.
The stronger final rule was highlighted in a Wells Fargo Securities research note distributed on Tuesday. The report said the CMS decision effectively guarantees that private health insurers will receive in excess of $13 billion in additional Medicare Advantage reimbursements from federal sources during the 2027 plan year.
Wells Fargo calculated the change from preliminary guidance to final rule at 239 basis points, a swing the analysts described as "meaningful" and one that shifts margin recovery for health plans onto firmer footing. The firm identified the primary cause of the upward revision as CMS's abandonment of a proposed revision to the Medicare risk model that appeared in the Advance Notice.
"The 2027 MA Final Rule improved significantly, leaving us much more confident that plans can improve margins," the analysts wrote. They also pointed out that typical year-over-year differences between preliminary and final rules usually run near 100 basis points, making this near-240 basis-point adjustment a notable surprise to market participants.
When Wells Fargo applies assumed "normal coding trends" of between 2% and 3%, the note estimates that public insurers now face implied revenue growth in the range of 6.0% to 6.5% for 2027. That implied revenue growth remains slightly below the firm's estimate of a 7% cost trend for Medicare Part A and Part B combined, but the analysts judged the resulting spread to be manageable.
The research note suggests insurers could bridge the remaining gap through "modest benefit reductions," a path that would, in the view of Wells Fargo, provide a clear line of sight to improved profitability in 2027 for plans exposed to the Medicare Advantage market.
Despite the improved outlook for Medicare Advantage, the Wells Fargo team retained a cautious stance on other areas of managed care. They said they are "clearly the most constructive" on the Medicare Advantage story while underscoring continued uncertainty around Medicaid and the health insurance Exchanges.
The CMS update delivers much-needed clarity for large insurers with substantial exposure to the private iteration of the government's program for seniors. Those plans have navigated a year of heightened regulatory scrutiny and cost pressures, and the final MA rates appear to relieve some of that strain for 2027.
Market context and implications
- Humana and other major Medicare Advantage-focused insurers saw immediate market gains following the CMS announcement.
- The 2.48% final rate implies material incremental federal funding for private MA plans in 2027, estimated at over $13 billion.
- Analysts view the outcome as supportive of margin recovery in MA, while expressing caution about Medicaid and Exchange segments of the managed-care market.